Structure Therapeutics (NASDAQ:GPCR) Lowered to Sell Rating by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other research firms also recently weighed in on GPCR. Citizens Jmp decreased their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research note on Friday, February 27th. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Morgan Stanley lifted their target price on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, Guggenheim upped their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Price Performance

GPCR stock opened at $45.92 on Friday. The company has a market capitalization of $3.25 billion, a PE ratio of -58.13 and a beta of -1.80. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90. The firm’s 50-day moving average is $68.79 and its 200 day moving average is $51.39.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Morgan Stanley raised its stake in Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after buying an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at $61,086,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.